意义不止当下,路漫漫其修远:评纳武利尤单抗联合XELOX/FOLFOX方案在HER2阴性晚期胃癌一线治疗中的应用和影响

摘要

cqvip:1文献来源Janjigian YY,Shitara K,Moehler M,et al.First-line nivolumab plus chemotherapy versus chemothera-py alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma(Check-Mate 649):A randomised,open-label,phase 3 trial[J].Lancet,2021,398(10294):27-40.